Eric M Ruderman, MD

Eric M Ruderman, MD


Dr. Ruderman attended medical school at Albert Einstein College of Medicine from 1983-87 after graduating from Princeton University with a degree in English literature.  He completed a residency in internal medicine at the Hospital of the University of Pennsylvania and a fellowship in rheumatology at Brigham and Women’s Hospital.  His research work during his fellowship resulted in publications in Arthritis and Rheumatism and Journal of Infectious Diseases.

After fellowship, Dr. Ruderman spent 6 years in private rheumatology practice before joining the faculty at Northwestern University, where he is currently an associate professor of medicine, clinical practice director for the rheumatology division, and co-director of a cooperative clinic for the management of psoriasis and psoriatic arthritis.  In addition to his clinical roles, Dr. Ruderman manages clinical trials in rheumatoid arthritis and other inflammatory arthritides and serves as a vice-chair of Northwestern University’s institutional review board. As a consequence of his research interests, Dr. Ruderman consults regularly on the development and utilization of rheumatologic therapeutics as well as serving on the data safety monitoring boards for several industry and NIH sponsored trials.

Dr. Ruderman is past president of the Chicago Rheumatism Society and serves on the board of the local chapter of the Arthritis Foundation.  He is a member of the Communications and Marketing Committee and the Drug Safety subcommittee of the American College of Rheumatology and is co-editor of the ACR’s Hotline newsletter.  He is a member of the Abstract Selection and Annual Meeting Planning Committees and chair of the planning committee for the Innovative Therapies Meeting of the ACR.  Dr. Ruderman is on the scientific advisory committee for the Coalition of Rheumatology Researchers of North America (CORRONA) and is a member of the editorial boards of Rheumatology and International Journal of Advances in Rheumatology.  He has authored numerous book chapters and is co-editor of the textbook Psoriasis and Psoriatic Arthritis: An Integrated Approach.


  1. EM Ruderman: Evaluation and management of psoriatic arthritis: The role of biologic therapy. J Am Acad Dermatol 49: 125-32 (2003).
  2. PJ Mease, DD Gladman, CT Ritchlin, EM Ruderman, et al.: Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 52(10): 3279-89 (2005).
  3. W Burton, A Morrison, R Maclean, EM Ruderman: Systematic review of studies of productivity loss due to rheumatoid arthritis. Occup Med 56(1): 18-27 (2006).
  4. ME Weinblatt, MH Schiff, EM Ruderman, CO Bingham, 3rd, J Li, J Louie, DE Furst: Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. Arthritis Rheum 58(7): 1921-30 (2008).
  5. L Statkute and EM Ruderman: Novel TNF antagonists for the treatment of rheumatoid arthritis. Expert Opin Investig Drugs 19(1): 105-15 (2010).
  6. EM Ruderman: Do we really need five TNF antagonists? Rheumatology. 49(6): 1028-9 (2010).
Bookmark and Share